Two peptidase activities decrease in treated bipolar disorder not schizophrenic patients

Bipolar Disorders

Volumn 6, Issue 2, 2004, Pages 156-161

  Breen, Gerome ^a,b   Harwood, Adrian J ^c   Gregory, Kathryn ^d   Sinclair, Maggie ^b   Collier, David ^a   St Clair, David ^b   Williams, Robin S B ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bipolar disorder; Plasma; Prolyl oligopeptidase; Z Pro prolinal insensitive peptidase; ZIP

Indexed keywords

LITHIUM; NEUROLEPTIC AGENT; PEPTIDASE; PROLYL ENDOPEPTIDASE;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; CYTOSOL; ENZYME ACTIVITY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PLASMA; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DIPEPTIDES; HUMANS; LITHIUM CARBONATE; NEURONS; SCHIZOPHRENIA; SERINE ENDOPEPTIDASES;

EID: 1842581793     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-5618.2004.00100.x     Document Type: Article

References (36)

1. Bauer M, Unutzer J, Pincus HA, Lawson WB. Bipolar disorder. Ment Health Serv Res 2002; 4: 225-229.
2. Johannessen JO. Schizophrenia - incidence and significance. Tidsskr Nor Laegeforen 2002; 122: 2011-2014.
3. McGuffin P, Katz R. The genetics of depression and manic-depressive disorder. Br J Psychiatry 1989; 155: 294-304.
4. McGuffin P, Owen MJ, Farmer AE. Genetic basis of schizophrenia. Lancet 1995; 346: 678-682.
5. Maes M, Goossens F, Scharpe S, Calabrese J, Desnyder R, Meltzer HY. Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: Effects of antidepressants, mood stabilizers, and antipsychotic drugs. Psychiatry Res 1995; 58: 217-225.
6. Maes M, Goossens F, Lin A, De MI, Van Gastel A, Scharpe S. Effects of psychological stress on serum prolyl endopeptidase and dipeptidyl peptidase IV activity in humans: Higher serum prolyl endopeptidase activity is related to stress-induced anxiety. Psychoneuroendocrinology 1998; 23: 485-495.
7. Maes M, Lin AH, Bonaccorso S et al. Higher serum prolyl endopeptidase activity in patients with post-traumatic stress disorder. J Affect Disord 1999; 53: 27-34.
8. Maes M, Libbrecht I, Lin A et al. Effects of pregnancy and delivery on serum prolyl endopeptidase (PEP) activity: Alterations in serum PEP are related to increased anxiety in the early puerperium and to postpartum depression. J Affect Disord 2000; 57: 125-137.
9. Maes M, Monteleone P, Bencivenga R et al. Lower serum activity of prolyl endopeptidase in anorexia and bulimia nervosa. Psychoneuroendocrinology 2001; 26: 17-26.
10. Maes M, Lin A, Bonaccorso S et al. Lower activity of serum peptidases in abstinent alcohol-dependent patients. Alcohol 1999; 17: 1-6.
11. Maes M, Goossens F, Scharpe S, Meltzer HY, D'Hondt P, Cosyns P. Lower serum prolyl endopeptidase enzyme activity in major depression: further evidence that peptidases play a role in the pathophysiology of depression. Biol Psychiatry 1994; 35: 545-552.
12. Maes M, Libbrecht I, Van Hunsel F et al. Lower serum activity of prolyl endopeptidase in fibromyalgia is related to severity of depressive symptoms and pressure hyperalgesia. Psychol Med 1998; 28: 957-965.
13. Hagihara M, Nagatsu T. Post-proline cleaving enzyme in human cerebrospinal fluid from control patients and parkinsonian patients. Biochem Med Metab Biol 1987; 38: 387-391.
14. Mantle D, Falkous G, Ishiura S, Blanchard PJ, Perry EK. Comparison of proline endopeptidase activity in brain tissue from normal cases and cases with Alzheimer's disease, Lewy body dementia, Parkinson's disease and Huntington's disease. Clin Chim Acta 1996; 249: 129-139.
15. Irazusta J, Larrinaga G, Gonzalez-Maeso J, Gil J, Meana JJ, Casis L. Distribution of prolyl endopeptidase activities in rat and human brain. Neurochem Int 2002; 40: 337-345.
16. Gallegos ME, Zannatha MM, Osornio EG, Sanchez AS, Posadas del rio FA. The activities of six exo-and endopeptidases in the substantia nigra, neostriatum, and cortex of the rat brain. Neurochem Res 1999; 24: 1557-1561.
17. Birney YA, O'Connor BF. Purification and characterization of a Z-pro-prolinal-insensitive Z-Gly-Pro-7-amino-4-methyl coumarin-hydrolyzing peptidase from bovine serum - a new proline-specific peptidase. Protein Expr Purif 2001; 22: 286-298.
18. Polgar L. The prolyl oligopeptidase family. Cell Mol Life Sci 2002; 59: 349-362.
19. Bellemere G, Morain P, Vaudry H, Jegou S. Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem 2003; 84: 919-929.
20. Williams RS, Eames M, Ryves WJ, Viggars J, Harwood AJ. Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate. EMBO J 1999; 18: 2734-2745.
21. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417: 292-295.
22. Augustyns K, Borloo M, Belyaev A et al. Synthesis of peptidyl acetals as inhibitors of prolyl endopeptidase. Bioorg Med Chem Lett 1995; 5: 1265-1270.
23. Demuth HU, Schlenzig D, Schierhorn A, Grosche G, Chapot-Chartier MP, Gripon JC. Design of (omega-N-(o-acyl)hydroxy amid) aminodicarboxylic acid pyrrolidides as potent inhibitors of proline-specific peptidases. FEBS Lett 1993; 320: 23-27.
24. Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: A unifying hypothesis. Cell 1989; 59: 411-419.
25. Schulz I, Gerhartz B, Neubauer A et al. Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition. Eur J Biochem 2002; 269: 5813-5820.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington DC: American Psychiatric Association, 2000.
27. McGuffin P, Farmer A, Harvey I. A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system. Arch Gen Psychiatry 1991; 48: 764-770.
28. Ohtsuki S, Homma K, Kurata S, Komano H, Natori S. A prolyl endopeptidase of Sarcophaga peregrina (flesh fly): Its purification and suggestion for its participation in the differentiation of the imaginal discs. J Biochem 1994; 115: 449-453.
29. Goossens F, De MI, Vanhoof G, Scharpe S. A sensitive method for the assay of serum prolyl endopeptidase. Eur J Clin Chem Clin Biochem 1992; 30: 235-238.
30. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Press, 2003.
31. Goossens F, De M I, Vanhoof G, Scharpe S. Distribution of prolyl oligopeptidase in human peripheral tissues and body fluids. Eur J Clin Chem Clin Biochem 1996; 34: 17-22.
32. Faivre-Bauman A, Knisatschek H, Tixier-Vidal A, Bauer K. Ontogenesis of neuropeptide degrading enzymes in the mouse brain. J Neurosci Res 1981; 6: 63-74.
33. Kato T, Nakano T, Kojima K, Nagatsu T, Sakakibara S. Changes in prolyl endopeptidase during maturation of rat brain and hydrolysis of substance P by the purified enzyme. J Neurochem 1980; 35: 527-535.
34. Martins AR, Izumi C, Pretel HS, De Mello FG. Ontogenesis of prolyl endopeptidase in the chick retina. Neurosci Lett 1987; 80: 89-94.
35. Laitinen KS, van Groen T, Tanila H, Venalainen J, Mannisto PT, Alafuzoff I. Brain prolyl oligopeptidase activity is associated with neuronal damage rather than beta-amyloid accumulation. Neuroreport 2001; 12: 3309-3312.
36. Gotoh H, Hagihara M, Nagatsu T, Iwata H, Miura T. Activity of dipeptidyl peptidase IV and post-proline cleaving enzyme in sera from osteoporotic patients. Clin Chem 1988; 34: 2499-2501.